Onkolojide İlaç Yeniden Konumlandırma: Biyokimyasal Temeller, Hesaplamalı Yaklaşımlar ve Klinik Uygulamalar

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery. 2004;3(8):673–683. doi:10.1038/nrd1468

Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844–853. doi:10.1001/jama.2020.1166

Sun D, Gao W, Hu H, et al. Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B. 2022;12(7):3049–3062. doi:10.1016/j.apsb.2022.02.002

Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery. 2019;18(1):41–58. doi:10.1038/nrd.2018.168

Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534(7607):314–316. doi:10.1038/534314a

Jourdan JP, Bureau R, Rochais C, et al. Drug repositioning: a brief overview. Journal of Pharmacy and Pharmacology. 2020;72(9):1145–1151. doi:10.1111/jphp.13273

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059

Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology & Oncology. 2019;12(1):134. doi:10.1186/s13045-019-0818-2

Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British Journal of Cancer. 2023;128(6):958–966. doi:10.1038/s41416-023-02204-2

Fontaine E. Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Frontiers in Endocrinology. 2018;9:753. doi:10.3389/fendo.2018.00753

Lamy S, Lachambre MP, Lord-Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascular Pharmacology. 2010;53(5–6):200–208. doi:10.1016/j.vph.2010.08.002

Chen D, Cui QC, Yang H, et al. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Research. 2006;66(21):10425–10433. doi:10.1158/0008-5472.CAN-06-2126

Kang X, Jadhav S, Annaji M, et al. Advancing cancer therapy with copper/disulfiram nanomedicines and drug delivery systems. Pharmaceutics. 2023;15(6):1567. doi:10.3390/pharmaceutics15061567

Juarez D, Fruman DA. Targeting the mevalonate pathway in cancer. Trends in Cancer. 2021;7(6):525–540. doi:10.1016/j.trecan.2020.11.008

Tripathi S, Gupta E, Galande S. Statins as anti-tumor agents: a paradigm for repurposed drugs. Cancer Reports. 2024;7(5):e2078. doi:10.1002/cnr2.2078

DepMap Consortium. DepMap: The Cancer Dependency Map Project. Available from: https://depmap.org (Accessed 15 February 2026).

Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437–1452.e17. doi:10.1016/j.cell.2017.10.049

Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–1935. doi:10.1126/science.1132939

Napolitano F, Carrella D, Mandriani B, et al. gene2drug: computational tool for drug repositioning. Bioinformatics. 2018;34(9):1498–1505. doi:10.1093/bioinformatics/btx8

Parisi D, Adasme MF, Sveshnikova A, et al. Drug repositioning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. Computational and Structural Biotechnology Journal. 2020;18:1043–1055. doi:10.1016/j.csbj.2020.04.004

Vanhaelen Q, Mamoshina P, Aliper AM, et al. Design of efficient computational workflows for in silico drug repurposing. Drug Discovery Today. 2017;22(2):210–222. doi:10.1016/j.drudis.2016.09.019

Ferreira LG, Andricopulo AD. Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. Drug Discovery Today. 2016;21(10):1699–1710. doi:10.1016/j.drudis.2016.06.021

Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for end-to-end drug discovery and development. Nature Materials. 2019;18(5):435–441. doi:10.1038/s41563-019-0338-z

Xia Y, Sun M, Huang H, et al. Drug repurposing for cancer therapy. Signal Transduction and Targeted Therapy. 2024;9(1):92. doi:10.1038/s41392-024-01808-1

Zhang Z, Ji J, Liu H. Drug repurposing in oncology: current evidence and future direction. Current Medicinal Chemistry. 2021;28(11):2175–2194. doi:10.2174/0929867327999200820124111

Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. British Journal of Pharmacology. 2018;175(2):168–180. doi:10.1111/bph.13798

Sleire L, Førde HE, Netland IA, et al. Drug repurposing in cancer. Pharmacological Research. 2017;124:74–91. doi:10.1016/j.phrs.2017.07.013

Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research. 2018;46(D1):D1074–D1082. doi:10.1093/nar/gkx1037

Hodos RA, Kidd BA, Shameer K, et al. In silico methods for drug repurposing and pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2016;8(3):186–210. doi:10.1002/wsbm.1337

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metabolism. 2016;23(1):27–47. doi:10.1016/j.cmet.2015.12.006

Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends in Biochemical Sciences. 2016;41(3):211–218. doi:10.1016/j.tibs.2015.12.001

Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381–405. doi:10.1016/j.cell.2017.04.001

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology. 2014;4:64. doi:10.3389/fonc.2014.00064

Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology. 2012;13(4):251–262. doi:10.1038/nrm3311

Vasan N, Baselga J, Hyman DM. Drug resistance in cancer. Nature. 2019;575(7782):299–309. doi:10.1038/s41586-019-1730-1

Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner. Cell Metabolism. 2010;11(5):390–401. doi:10.1016/j.cmet.2010.03.014

Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clinical Science. 2012;122(6):253–270. doi:10.1042/CS20110386

Clendening JW, Penn LZ. Targeting tumor cell metabolism with statins. Oncogene. 2012;31(48):4967–4978. doi:10.1038/onc.2012.6

Thurnher M, Gruenbacher G, Nussbaumer O. Regulation of mevalonate metabolism in cancer and immune cells. Biochimica et Biophysica Acta. 2013;1831(6):1009–1015. doi:10.1016/j.bbalip.2013.03.003

Skrott Z, Mistrik M, Andersen KK, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552(7684):194–199. doi:10.1038/nature25016

Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clinical Cancer Research. 2012;18(5):1201–1206. doi:10.1158/1078-0432.CCR-11-0641

Elmore S. Apoptosis: a review of programmed cell death. Toxicologic Pathology. 2007;35(4):495–516. doi:10.1080/01926230701320337

Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348. doi:10.1038/35077213

White E. The role for autophagy in cancer. Journal of Clinical Investigation. 2015;125(1):42–46. doi:10.1172/JCI73941

Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nature Reviews Cancer. 2017;17(2):93–115. doi:10.1038/nrc.2016.138

Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Research. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962

Arneth B. Tumor microenvironment. Medicina. 2019;56(1):15. doi:10.3390/medicina56010015

Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025

Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–1750. doi:10.1016/S0140-6736(10)61543-7

Chae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767–40780. doi:10.18632/oncotarget.8194

Embaby A, Heinhuis KM, IJzerman NS, et al. Propranolol monotherapy in angiosarcoma – a window-of-opportunity study (PropAngio). European Journal of Cancer. 2024;202:113974. doi:10.1016/j.ejca.2024.113974

Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809. doi:10.18632/oncotarget.343

Kelley KC, Grossman KF, Brittain-Blankenship M, et al. A phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer. 2021;21(1):510. doi:10.1186/s12885-021-08242-4

Zhong S, Zhang X, Chen L, et al. Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treatment Reviews. 2015;41(6):554–567. doi:10.1016/j.ctrv.2015.04.005

Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. International Journal of Cancer. 2008;123(4):899–904. doi:10.1002/ijc.23550

Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41. doi:10.1016/S0140-6736(10)62110-1

Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery. 2019;18(6):463–477. doi:10.1038/s41573-019-0024-5

Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas pan-cancer analysis project. Nature Genetics. 2013;45(10):1113–1120. doi:10.1038/ng.2764

Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a Cancer Dependency Map. Cell. 2017;170(3):564–576.e16. doi:10.1016/j.cell.2017.06.010

Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503–508. doi:10.1038/s41586-019-1186-3

Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570–575. doi:10.1038/nature11005

Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166(3):740–754. doi:10.1016/j.cell.2016.06.017

Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. doi:10.1038/nature11003

Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery. 2004;3(11):935–949. doi:10.1038/nrd1549

Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. British Journal of Pharmacology. 2007;152(1):9–20. doi:10.1038/sj.bjp.0707305

Zitnik M, Nguyen F, Wang B, et al. Machine learning for integrating data in biology and medicine: principles, practice, and opportunities. Information Fusion. 2019;50:71–91. doi:10.1016/j.inffus.2018.09.012

Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e13. doi:10.1016/j.cell.2020.01.021

Guney E, Menche J, Vidal M, et al. Network-based in silico drug efficacy screening. Nature Communications. 2016;7:10331. doi:10.1038/ncomms10331

Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nature Reviews Genetics. 2011;12(1):56–68. doi:10.1038/nrg2918

Oprea TI, Overington JP. Computational and practical aspects of drug repositioning. Assay and Drug Development Technologies. 2015;13(6):299–306. doi:10.1089/adt.2015.29011

Verbaanderd C, Meheus L, Huys I, et al. Repurposing drugs in oncology: next steps. Trends in Cancer. 2017;3(8):543–546. doi:10.1016/j.trecan.2017.06.007

Breckenridge A, Jacob R. Overcoming the legal and regulatory barriers to drug repurposing. Nature Reviews Drug Discovery. 2019;18(1):1–2. doi:10.1038/nrd.2018.92

U.S. Food and Drug Administration. Determining whether to submit an ANDA or a 505(b)(2) application: guidance for industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-whether-submit-anda-or-505b2-application (Accessed 15 February 2026).

Asker-Hagelberg C, Boran T, Bouygues C, et al. Repurposing of medicines in the EU: launch of a pilot framework. Frontiers in Medicine. 2022;8:817663. doi:10.3389/fmed.2021.817663

U.S. Food and Drug Administration. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug-and-biological-products (Accessed 15 February 2026).

Nicora G, Vitali F, Dagliati A, et al. Integrated multi-omics analyses in oncology: a review of machine learning methods and tools. Frontiers in Oncology. 2020;10:1030. doi:10.3389/fonc.2020.01030

Pan X, Lin X, Cao D, et al. Deep learning for drug repurposing: methods, databases, and applications. WIREs Computational Molecular Science. 2022;12(4):e1597. doi:10.1002/wcms.1597

Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Annals of Oncology. 2017;28(1):34–43. doi:10.1093/annonc/mdw413

Jarada TN, Rokne JG, Alhajj R. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. Journal of Cheminformatics. 2020;12(1):46. doi:10.1186/s13321-020-00450-7

Corsello SM, Bittker JA, Liu Z, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nature Medicine. 2017;23(4):405–408. doi:10.1038/nm.4306